Regular review: tumour markers in malignancies
- PMID: 10669448
- PMCID: PMC1117546
- DOI: 10.1136/bmj.320.7232.424
Regular review: tumour markers in malignancies
Erratum in
- BMJ 2000 Mar 25;320(7238):867
Figures
Comment in
-
Tumour markers in malignancies. Two isoforms of oestrogen receptor are now known to exist.BMJ. 2000 Aug 5;321(7257):379-80. BMJ. 2000. PMID: 10991559 Free PMC article. No abstract available.
-
Tumour markers in malignancies. CA19.9 is useful in several cancers.BMJ. 2000 Aug 5;321(7257):380. BMJ. 2000. PMID: 10991560 No abstract available.
-
Tumour markers in malignancies. Monocolonal immunoglobulin and beta human chorionic gonadotrophin.BMJ. 2000 Aug 5;321(7257):380. BMJ. 2000. PMID: 10991561 No abstract available.
References
-
- Melo JV. The molecular biology of chronic myeloid leukemia. Leukemia. 1996;10:751–756. - PubMed
-
- Heim S, Mitelmann F. Cancer cytogenetics. Chromosomal and molecular genetic aberrations of tumor cells. 2nd ed. New York: Wiley; 1994.
-
- Hunerbein M. The value of tumor markers in colorectal cancer. Recent Results Cancer Res. 1998;146:48–55. - PubMed
-
- Lamerz R. AFP isoforms and their clinical significance. Anticancer Res. 1997;17:2927–2930. - PubMed
-
- Kuban DA, El-Mahdi A, Schellhammer PF. PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it? Semin Oncol. 1998;8:72–80. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources